Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
KODthis companyKodiak Sciences Inc.	$105.57	-6.47×	9.45×	0×	-7.06×	-99.2%	0.0%	0.0%	0.0%	-146.1%	-73.7%	-9.2%	1.01×	0.25×	0×	4.72×	0.0%	1	7.23	1	D+
BLTEBelite Bio, Inc	$156.02	-69.25×	6.96×	0×	-64.97×	-93.2%	0.0%	0.0%	0.0%	-10.1%	-10.9%	-0.7%	0×	4.57×	0×	50.02×	0.0%	2	250.43	1	D+
EYPTEyePoint Pharmaceuticals, Inc.	$0.35	-5.76×	4.37×	42.66×	-5.49×	-1218.8%	93.4%	-776.0%	-739.4%	-75.8%	-74.0%	-18.2%	0.07×	0.34×	0×	8.88×	0.0%	2	-11.09	1	C-
FDMT4D Molecular Therapeutics, Inc.	$12.43	-3.1×	0.86×	5.1×	-2.99×	-184.8%	91.1%	-187.2%	-164.4%	-27.7%	-30.2%	-25.1%	0.04×	0.29×	0×	9.39×	0.0%	3	1.71	2	C
KPRXKiora Pharmaceuticals, Inc.	$1.49	-0.75×	0.5×	0×	0.02×	56.4%	0.0%	0.0%	0.0%	-67.2%	-40.7%	-124.6%	0.02×	0.69×	-473.91×	5.99×	0.0%	2	-9.47	3	B-
OCGNOcugen, Inc.	$0.94	-5.87×	-33.31×	91.83×	-6.97×	-126.5%	45.9%	-1425.7%	-1537.4%	557.7%	-278.6%	-14.1%	-2.72×	-0.24×	-12.13×	1.06×	0.0%	2	-6.2	2	C
Peer median	—	-5.76×	0.86×	5.1×	-5.49×	-126.5%	45.9%	-187.2%	-164.4%	-27.7%	-40.7%	-18.2%	0.02×	0.34×	0×	8.88×	0.0%	2	-6.2	2	—